Aufsatz(gedruckt)2004

The FDA's antibiotic resistance

In: Regulation: the Cato review of business and government, Band 27, Heft 4, S. 34-37

Verfügbarkeit an Ihrem Standort wird überprüft

Abstract

Argues that current demand-side policy of the Food and Drug Administration and the Centers for Disease Control is the wrong route to address the issue of antibiotic resistance as it reduces the value to a pharmaceutical company of investing in the creation of new antibiotics. In this light, three externalities associated with antibiotic usage are discussed: public health, antibiotic resistance, and supply-side externalities. A cost-benefit analysis of FDA policies related to increased antibiotic scrutiny ensues, finding that requiring additional testing for antibiotics makes little sense with respect to patient welfare. Two harmful effects on antibiotic resistance of this FDA policy are denying the market use of an additional antibiotic, Ketek, and the loss of pharmaceutical company incentive to develop new antibiotics.

Problem melden

Wenn Sie Probleme mit dem Zugriff auf einen gefundenen Titel haben, können Sie sich über dieses Formular gern an uns wenden. Schreiben Sie uns hierüber auch gern, wenn Ihnen Fehler in der Titelanzeige aufgefallen sind.